Table 1.
Summary of vaccine efficacy and 95% confidence intervals from two pivotal efficacy studies by age: Zostavax Efficacy and Safety Trial (ZEST) in individuals aged 50–59 years and Shingles Prevention Study (SPS) in individuals aged ⩾60 years.
| ZEST |
SPS |
|||||
|---|---|---|---|---|---|---|
| 50–59 years | ⩾60 years | 60–69 years | ⩾70 years | 70–79 years | ⩾80 years | |
| Vaccinated/placebo N | 11,211/11,228 | 19,254/19,247 | 10,370/10,356 | 8884/8891 | 7621/7759 | 1263/1332 |
| HZ incidence | 70% (54%; 81%) | 51% (44%; 58%) | 64% (56%; 71%) | 38% (25%; 48%) | 41% (28%; 52%) | 18% (<0%; 48%) |
| PHN incidence | Not evaluated | 67% (48%; 79%) | 66% (20%; 37%) | 67% (43%; 81%) | 74% (49%; 87%) | 40% (<0%; 67%) |
| % PHN among HZ | Not evaluated | 39% (7%; 59%) | 5% (<0%; 56%) | 47% (13%; 67%) | 55% (18%; 52%) | 26% (<0%; 68%) |
| BOI* | 73% (53%; 85%) | 61% (51%; 69%) | 66% (52%; 76%) | 55% (40%; 67%) | 59% (43%; 71%) | 38% (<0%; 67%) |
*
BOI: burden of illness; incidence, severity and duration of acute and chronic HZ-associated pain. In ZEST D0-D21, in SPS D0-D182.
HZ, herpes zoster; PHN, postherpetic neuralgia.